NP-120 by Algernon Pharmaceuticals Inc. to treat Idiopathic Pulmonary Fibrosis

A clinical stage pharmaceutical development firm, Algernon Pharmaceuticals Inc. made an announcement that NP-120, its repurposed pioneering candidate to treat idiopathic pulmonary fibrosis, exhibited superiority in the reduction of fibrosis over two globally approved therapies for Nintedanib, idiopathic pulmonary fibrosis, Pirfenidone &, in a well-established in vivo animal model study of idiopathic pulmonary fibrosis.

Data from this study showed a statistically significant improvement in established fibrosis in a twenty-one-day bleomycin mouse model. The treatment began on 7th Day.

Nintedanib (40 milligrams/kg, QD), a positive control and comparator arm, and NP-251 (30 milligrams/kg, TID) both exhibited a 51 percent reduction in fibrosis versus untreated controls.

Pirfenidone (100 milligrams/kg, BID), both a positive control and comparator arm in the study, showed a 44 percent reduction in fibrosis versus untreated controls which were not statistically significant as measured by Trichrome staining & modified Ashcroft scoring.

NP-120 (20 milligrams/kg, TID) showed a 56 percent reduction in fibrosis versus untreated controls.

In experiments which were done prior to this, NP-121, which shares the same target and similar pharmacology as NP-120, also reduced fibrosis to a similar level as NP-120 at the same dose, suggesting a class effect of the pharmacophore.

NP-120 is a drug used at present for neurological indications in Japan and was initially developed by a global top ten pharmaceutical firm. NP-121 is a repositioned drug that has undergone extensive Phase II and III testing.

The Chief Executive Officer of Algernon Pharmaceuticals, Christopher J Moreau stated that they have now completed 2 studies from an independent lab, affirming that NP-120 is an effective anti-fibrotic agent for idiopathic pulmonary fibrosis. He further said that they believe NP-120 could represent a new approach for the treatment of idiopathic pulmonary fibrosis and they look forward to advancing their lead into a Phase II clinical trial as soon as possible to establish human efficacy.